Active surveillance for prostate cancer: progress and promise
about
Mechanistic Insights into Molecular Targeting and Combined Modality Therapy for Aggressive, Localized Prostate CancerScreening and detection advances in magnetic resonance image-guided prostate biopsyProstate cancer: ESMO Consensus Conference Guidelines 2012The role of single nucleotide polymorphisms in predicting prostate cancer risk and therapeutic decision makingActive surveillance for prostate cancer: current evidence and contemporary state of practiceLoss of tumor suppressor mir-203 mediates overexpression of LIM and SH3 Protein 1 (LASP1) in high-risk prostate cancer thereby increasing cell proliferation and migration.Prostate specific antigen: the past, present and future.A reference set of health utilities for long-term survivors of prostate cancer: population-based data from Ontario, Canada.Using routinely collected data to stratify prostate cancer patients into phases of care in the United Kingdom: implications for resource allocation and the cancer survivorship programme.Analytical validation of the Oncotype DX prostate cancer assay - a clinical RT-PCR assay optimized for prostate needle biopsiesCancer/Testis Antigens: "Smart" Biomarkers for Diagnosis and Prognosis of Prostate and Other CancersOptimizing mouse models for precision cancer prevention.Quality-of-life effects of prostate-specific antigen screening.Metabolic imaging of patients with prostate cancer using hyperpolarized [1-¹³C]pyruvateInvestigation of miR-21, miR-141, and miR-221 expression levels in prostate adenocarcinoma for associated risk of recurrence after radical prostatectomy.[Focal prostate cancer therapy: capabilities, limitations and prospects].The role of MRI in prostate cancer active surveillance.Multiparametric-MRI and Targeted Biopsies in the Management of Prostate Cancer Patients on Active SurveillanceCharacteristics and experiences of patients with localized prostate cancer who left an active surveillance program.Use of treatment information from a state central cancer registry in prostate cancer research.Decision making and cancer.miR-19, miR-345, miR-519c-5p serum levels predict adverse pathology in prostate cancer patients eligible for active surveillance.Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohortGene-expression analysis of gleason grade 3 tumor glands embedded in low- and high-risk prostate cancer.Methylome-wide Sequencing Detects DNA Hypermethylation Distinguishing Indolent from Aggressive Prostate CancerA System Dynamics Model of Serum Prostate-Specific Antigen Screening for Prostate Cancer.Commentary on the State-of-the-Science Conference on the role of active surveillance in the management of men with localized prostate cancer.Active surveillance for prostate cancer: an underutilized opportunity for reducing harm.Targeted biopsy in the detection of prostate cancer using an office based magnetic resonance ultrasound fusion deviceApplying ecological and evolutionary theory to cancer: a long and winding road.Mitochondrial oncobioenergetic index: A potential biomarker to predict progression from indolent to aggressive prostate cancer.Prostate cancer mortality following active surveillance versus immediate radical prostatectomy.Guideline-discordant androgen deprivation therapy in localized prostate cancer: patterns of use in the medicare population and cost implications.Many young men with prostate-specific antigen (PSA) screen-detected prostate cancers may be candidates for active surveillance.Active surveillance for prostate cancer compared with immediate treatment: an economic analysisSerial Magnetic Resonance Imaging in Active Surveillance of Prostate Cancer: Incremental ValueDivorcing diagnosis from treatment: contemporary management of low-risk prostate cancer.Clinically available RNA profiling tests of prostate tumors: utility and comparisonTreatment and Mortality in Men with Localized Prostate Cancer: A Population-Based Study in California.Guttiferone K impedes cell cycle re-entry of quiescent prostate cancer cells via stabilization of FBXW7 and subsequent c-MYC degradation
P2860
Q26766638-EFE75B1C-4920-48ED-A96D-48E7B10152D3Q26991785-A202D0F0-DCFC-4C99-861E-027516F0BC7EQ27022847-EEFC2EAA-010E-45E1-972D-F5FA2FD23F64Q27025062-DCDC9B29-D8CB-4620-8384-0D254DDDB73DQ28066534-8B9026A3-7BD1-46C4-8F34-14B617E52868Q30009388-133D1214-8922-4440-B12F-36B847989A2DQ30436923-83ED8782-44F3-44A7-B05F-78072D72DD14Q30613075-C6E7019A-ECE2-4460-A6CA-F61A6F52E976Q30912685-1F9DA26A-BE4A-45FA-B72D-737F5166A09AQ33557377-2F2B923B-C2BD-4AC0-99DA-E725E5EE6264Q33624448-3FA3F981-D5DD-44D5-8DAC-FAB0BC44D266Q33919192-5FE43FDE-AB9E-40FA-96CB-01BFE9D3E218Q34294102-B63525FF-E975-4F8F-A23A-23473E530AA8Q34359533-ED650B9A-9ACC-4A77-AA22-5AD0B2752D47Q34381845-00BA8B86-B8C4-4455-8B13-5E2F28134756Q34448994-94C72E02-E8B2-4B64-87E9-DFAD92CD93CDQ34705261-88194159-57EC-4C31-B6A8-A2999107D27CQ35012617-66108B5A-59FA-42E9-95EC-A707B5BA9356Q35095972-15C43D67-3A24-40E6-8E61-F1E19072BCB7Q35124541-89EB7779-A615-4DE3-A420-499EAA23C7F3Q35142194-3034EB3A-C5C9-4444-8874-C0F06B624A66Q35180831-2F32CC4C-2571-4316-B196-9BDBF62A12DDQ35909631-352107D1-039A-46AE-A9FC-650E9C276D12Q36021088-23E49D74-9E6C-464D-84B9-990A39D42D83Q36386969-5F5B9551-6CD7-432B-8578-9C2E1B1D0754Q36493623-0D35AB21-5FC1-42BC-A453-CB212C4F8621Q36520434-90588B5A-ECE6-4D53-A52C-168411CF0CABQ36520443-6BDE1557-C9B5-4584-8029-972878FDA0C9Q36579232-4CAA86CC-A2F8-4249-A31F-198293FC265CQ36595749-D24CB453-7EA7-4A45-8AC7-55CBD1725379Q36619120-33AB33AC-3D9F-4C65-BDAD-32CFC27E48BFQ36706936-C2A3017B-27D7-443C-AFFE-3F3099D606DEQ36776998-25E3EB39-146D-45C2-BBCC-6C170B6F1FCDQ36798276-A125D747-182E-4FF1-9C9F-55176447FB19Q36973544-16BD6BD5-22CB-493E-8FC6-8BF0CBDBEF93Q36988608-49B8C296-0A37-43D0-A4B2-55579ECEA0C7Q37025434-2C000E0B-3DF9-4286-9165-611E678FF009Q37113181-64C7479B-1F6E-46C1-A187-800DF8BF920FQ37134562-69CB64AF-FD69-4EAC-B2CB-A42079E53B1CQ37482721-AC9C1D13-03EE-49C9-AB1D-234FDE805E74
P2860
Active surveillance for prostate cancer: progress and promise
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Active surveillance for prostate cancer: progress and promise
@ast
Active surveillance for prostate cancer: progress and promise
@en
Active surveillance for prostate cancer: progress and promise
@nl
type
label
Active surveillance for prostate cancer: progress and promise
@ast
Active surveillance for prostate cancer: progress and promise
@en
Active surveillance for prostate cancer: progress and promise
@nl
prefLabel
Active surveillance for prostate cancer: progress and promise
@ast
Active surveillance for prostate cancer: progress and promise
@en
Active surveillance for prostate cancer: progress and promise
@nl
P3181
P356
P1476
Active surveillance for prostate cancer: progress and promise
@en
P2093
Peter R Carroll
P304
P3181
P356
10.1200/JCO.2011.34.9738
P407
P577
2011-09-20T00:00:00Z